Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Acute Kidney Injury I: Introduction

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Insulin Pathway Changes in Localized Prostate Cancer: A Multi-Institutional Analysis.

Cancers·2026

Same author

Understanding what surgical advanced practice providers want: A survey of autonomy, tasks, and training preferences across three institutions.

American journal of surgery·2026

Same author

Perioperative therapies for metastatic renal cell carcinoma.

Journal of cancer metastasis and treatment·2026

Same author

Using ctDNA to Inform Adjuvant Therapy for Urologic Malignancies.

Cancers·2026

Same author

Clinical management of oligoprogressive renal cell carcinoma.

Expert review of anticancer therapy·2026

Same author

Unclear territory: navigating metastatic nonclear cell renal cell carcinoma.

Current opinion in oncology·2026

Search research articles

Related Experiment Video

Updated: Jul 16, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Risk Stratification in Renal Cell Carcinoma: A Narrative Review.

Nykiera Dixon¹, Vivian Wong¹, Fuat Bicer²

¹Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.

|July 15, 2026

Summary

This review explores risk stratification for renal cell carcinoma (RCC), a common kidney cancer. Emerging molecular biomarkers show promise for improving prognostic accuracy beyond current clinical models.

Keywords:

localized renal cell carcinoma metastatic renal cell carcinoma renal cell carcinoma risk categorization risk stratification

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Related Experiment Videos

Last Updated: Jul 16, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Area of Science:

Oncology
Genitourinary Pathology
Cancer Prognostics

Background:

Renal cell carcinoma (RCC) is a significant cause of cancer diagnoses and deaths in the US.
Accurate risk stratification is crucial for patient management and clinical trial development in RCC.
Current prognostic models often overlook the molecular complexity of RCC.

Purpose of the Study:

To review and compare established and novel risk stratification and prognostic models for all stages of RCC.
To highlight the limitations of current clinical and pathological models.
To discuss the potential of emerging molecular biomarkers.

Main Methods:

This is a narrative review synthesizing existing literature on RCC risk stratification.
Established models (IMDC, SSIGN) were compared with emerging biomarker approaches.
The review focuses on prognostic performance and limitations.

Main Results:

Established models like IMDC and SSIGN provide robust prognostication but rely on indirect measures of tumor biology.
Emerging biomarkers including ctDNA, methylated DNA, radiomics, and molecular signatures show potential for enhanced risk discrimination.
Significant molecular heterogeneity exists within RCC, impacting current prognostic capabilities.

Conclusions:

Current RCC risk stratification models, while useful, do not fully capture tumor biology due to molecular heterogeneity.
Emerging molecular biomarkers offer a promising avenue for improving prognostic accuracy in RCC.
Integrated molecular-clinical-pathologic tools are needed for precise, individualized RCC patient care.